Cargando…

Liver Metabolomics and Inflammatory Profiles in Mouse Model of Fentanyl Overdose Treated with Beta-Lactams

Fentanyl is a highly potent opioid analgesic that is approved medically to treat acute and chronic pain. There is a high potential for overdose-induced organ toxicities, including liver toxicity, and this might be due to the increase of recreational use of opioids. Several preclinical studies have d...

Descripción completa

Detalles Bibliográficos
Autores principales: Alasmari, Fawaz, Alasmari, Mohammed S., Assiri, Mohammed A., Alswayyed, Mohammed, Rizwan Ahamad, Syed, Alhumaydhi, Abdulrahman I., Arif, Bandar I., Aljumayi, Sahar R., AlAsmari, Abdullah F., Ali, Nemat, Childers, Wayne E., Abou-Gharbia, Magid, Sari, Youssef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10456707/
https://www.ncbi.nlm.nih.gov/pubmed/37623908
http://dx.doi.org/10.3390/metabo13080965
_version_ 1785096764126134272
author Alasmari, Fawaz
Alasmari, Mohammed S.
Assiri, Mohammed A.
Alswayyed, Mohammed
Rizwan Ahamad, Syed
Alhumaydhi, Abdulrahman I.
Arif, Bandar I.
Aljumayi, Sahar R.
AlAsmari, Abdullah F.
Ali, Nemat
Childers, Wayne E.
Abou-Gharbia, Magid
Sari, Youssef
author_facet Alasmari, Fawaz
Alasmari, Mohammed S.
Assiri, Mohammed A.
Alswayyed, Mohammed
Rizwan Ahamad, Syed
Alhumaydhi, Abdulrahman I.
Arif, Bandar I.
Aljumayi, Sahar R.
AlAsmari, Abdullah F.
Ali, Nemat
Childers, Wayne E.
Abou-Gharbia, Magid
Sari, Youssef
author_sort Alasmari, Fawaz
collection PubMed
description Fentanyl is a highly potent opioid analgesic that is approved medically to treat acute and chronic pain. There is a high potential for overdose-induced organ toxicities, including liver toxicity, and this might be due to the increase of recreational use of opioids. Several preclinical studies have demonstrated the efficacy of beta-lactams in modulating the expression of glutamate transporter-1 (GLT-1) in different body organs, including the liver. The upregulation of GLT-1 by beta-lactams is associated with the attenuation of hyperglutamatergic state, which is a characteristic feature of opioid use disorders. A novel experimental beta-lactam compound with no antimicrobial properties, MC-100093, has been developed to attenuate dysregulation of glutamate transport, in part by normalizing GLT-1 expression. A previous study showed that MC-100093 modulated hepatic GLT-1 expression with subsequent attenuation of alcohol-increased fat droplet content in the liver. In this study, we investigated the effects of fentanyl overdose on liver metabolites, and determined the effects of MC-100093 and ceftriaxone in the liver of a fentanyl overdose mouse model. Liver samples from control, fentanyl overdose, and fentanyl overdose ceftriaxone- or MC-100093-treated mice were analyzed for metabolomics using gas chromatography–mass spectrometry. Heatmap analysis revealed that both MC-100093 and ceftriaxone attenuated the effects of fentanyl overdose on several metabolites, and MC-100093 showed superior effects. Statistical analysis showed that MC-100093 reversed the effects of fentanyl overdose in some metabolites. Moreover, enrichment analysis revealed that the altered metabolites were strongly linked to the glucose-alanine cycle, the Warburg effect, gluconeogenesis, glutamate metabolism, lactose degradation, and ketone body metabolism. The changes in liver metabolites induced by fentanyl overdose were associated with liver inflammation, an effect attenuated with ceftriaxone pre-treatments. Ceftriaxone normalized fentanyl-overdose-induced changes in liver interleukin-6 and cytochrome CYP3A11 (mouse homolog of human CYP3A4) expression. Our data indicate that fentanyl overdose impaired liver metabolites, and MC-100093 restored certain metabolites.
format Online
Article
Text
id pubmed-10456707
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104567072023-08-26 Liver Metabolomics and Inflammatory Profiles in Mouse Model of Fentanyl Overdose Treated with Beta-Lactams Alasmari, Fawaz Alasmari, Mohammed S. Assiri, Mohammed A. Alswayyed, Mohammed Rizwan Ahamad, Syed Alhumaydhi, Abdulrahman I. Arif, Bandar I. Aljumayi, Sahar R. AlAsmari, Abdullah F. Ali, Nemat Childers, Wayne E. Abou-Gharbia, Magid Sari, Youssef Metabolites Article Fentanyl is a highly potent opioid analgesic that is approved medically to treat acute and chronic pain. There is a high potential for overdose-induced organ toxicities, including liver toxicity, and this might be due to the increase of recreational use of opioids. Several preclinical studies have demonstrated the efficacy of beta-lactams in modulating the expression of glutamate transporter-1 (GLT-1) in different body organs, including the liver. The upregulation of GLT-1 by beta-lactams is associated with the attenuation of hyperglutamatergic state, which is a characteristic feature of opioid use disorders. A novel experimental beta-lactam compound with no antimicrobial properties, MC-100093, has been developed to attenuate dysregulation of glutamate transport, in part by normalizing GLT-1 expression. A previous study showed that MC-100093 modulated hepatic GLT-1 expression with subsequent attenuation of alcohol-increased fat droplet content in the liver. In this study, we investigated the effects of fentanyl overdose on liver metabolites, and determined the effects of MC-100093 and ceftriaxone in the liver of a fentanyl overdose mouse model. Liver samples from control, fentanyl overdose, and fentanyl overdose ceftriaxone- or MC-100093-treated mice were analyzed for metabolomics using gas chromatography–mass spectrometry. Heatmap analysis revealed that both MC-100093 and ceftriaxone attenuated the effects of fentanyl overdose on several metabolites, and MC-100093 showed superior effects. Statistical analysis showed that MC-100093 reversed the effects of fentanyl overdose in some metabolites. Moreover, enrichment analysis revealed that the altered metabolites were strongly linked to the glucose-alanine cycle, the Warburg effect, gluconeogenesis, glutamate metabolism, lactose degradation, and ketone body metabolism. The changes in liver metabolites induced by fentanyl overdose were associated with liver inflammation, an effect attenuated with ceftriaxone pre-treatments. Ceftriaxone normalized fentanyl-overdose-induced changes in liver interleukin-6 and cytochrome CYP3A11 (mouse homolog of human CYP3A4) expression. Our data indicate that fentanyl overdose impaired liver metabolites, and MC-100093 restored certain metabolites. MDPI 2023-08-21 /pmc/articles/PMC10456707/ /pubmed/37623908 http://dx.doi.org/10.3390/metabo13080965 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Alasmari, Fawaz
Alasmari, Mohammed S.
Assiri, Mohammed A.
Alswayyed, Mohammed
Rizwan Ahamad, Syed
Alhumaydhi, Abdulrahman I.
Arif, Bandar I.
Aljumayi, Sahar R.
AlAsmari, Abdullah F.
Ali, Nemat
Childers, Wayne E.
Abou-Gharbia, Magid
Sari, Youssef
Liver Metabolomics and Inflammatory Profiles in Mouse Model of Fentanyl Overdose Treated with Beta-Lactams
title Liver Metabolomics and Inflammatory Profiles in Mouse Model of Fentanyl Overdose Treated with Beta-Lactams
title_full Liver Metabolomics and Inflammatory Profiles in Mouse Model of Fentanyl Overdose Treated with Beta-Lactams
title_fullStr Liver Metabolomics and Inflammatory Profiles in Mouse Model of Fentanyl Overdose Treated with Beta-Lactams
title_full_unstemmed Liver Metabolomics and Inflammatory Profiles in Mouse Model of Fentanyl Overdose Treated with Beta-Lactams
title_short Liver Metabolomics and Inflammatory Profiles in Mouse Model of Fentanyl Overdose Treated with Beta-Lactams
title_sort liver metabolomics and inflammatory profiles in mouse model of fentanyl overdose treated with beta-lactams
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10456707/
https://www.ncbi.nlm.nih.gov/pubmed/37623908
http://dx.doi.org/10.3390/metabo13080965
work_keys_str_mv AT alasmarifawaz livermetabolomicsandinflammatoryprofilesinmousemodeloffentanyloverdosetreatedwithbetalactams
AT alasmarimohammeds livermetabolomicsandinflammatoryprofilesinmousemodeloffentanyloverdosetreatedwithbetalactams
AT assirimohammeda livermetabolomicsandinflammatoryprofilesinmousemodeloffentanyloverdosetreatedwithbetalactams
AT alswayyedmohammed livermetabolomicsandinflammatoryprofilesinmousemodeloffentanyloverdosetreatedwithbetalactams
AT rizwanahamadsyed livermetabolomicsandinflammatoryprofilesinmousemodeloffentanyloverdosetreatedwithbetalactams
AT alhumaydhiabdulrahmani livermetabolomicsandinflammatoryprofilesinmousemodeloffentanyloverdosetreatedwithbetalactams
AT arifbandari livermetabolomicsandinflammatoryprofilesinmousemodeloffentanyloverdosetreatedwithbetalactams
AT aljumayisaharr livermetabolomicsandinflammatoryprofilesinmousemodeloffentanyloverdosetreatedwithbetalactams
AT alasmariabdullahf livermetabolomicsandinflammatoryprofilesinmousemodeloffentanyloverdosetreatedwithbetalactams
AT alinemat livermetabolomicsandinflammatoryprofilesinmousemodeloffentanyloverdosetreatedwithbetalactams
AT childerswaynee livermetabolomicsandinflammatoryprofilesinmousemodeloffentanyloverdosetreatedwithbetalactams
AT abougharbiamagid livermetabolomicsandinflammatoryprofilesinmousemodeloffentanyloverdosetreatedwithbetalactams
AT sariyoussef livermetabolomicsandinflammatoryprofilesinmousemodeloffentanyloverdosetreatedwithbetalactams